Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N= 9484)

ML Molendijk, P Spinhoven, M Polak, BAA Bus… - Molecular …, 2014 - nature.com
Abstract Meta-analyses, published in 2008–2010, have confirmed abnormally low serum
brain-derived neurotrophic factor (BDNF) concentrations in depressed patients and …

BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis

M Polyakova, K Stuke, K Schuemberg, K Mueller… - Journal of affective …, 2015 - Elsevier
Background Peripheral brain-derived neurotrophic factor (BDNF) is decreased in acute
major depressive disorder (MDD) and bipolar disorder (BD) and recovered after treatment …

Serum levels of brain-derived neurotrophic factor in major depressive disorder: state–trait issues, clinical features and pharmacological treatment

ML Molendijk, BA Bus, P Spinhoven… - Molecular …, 2011 - nature.com
Recent evidence supports 'the neurotrophin hypothesis of depression'in its prediction that
brain-derived neurotrophic factor (BDNF) is involved in depression. However, some key …

The role of BDNF in the neuroimmune axis regulation of mood disorders

Y **, LH Sun, W Yang, RJ Cui, SB Xu - Frontiers in neurology, 2019 - frontiersin.org
The neuroimmune system plays a crucial role in the regulation of mood disorders. Moreover,
recent studies show that brain-derived neurotrophic factor (BDNF), a member of the …

Serum and plasma BDNF levels in major depression: a replication study and meta-analyses

L Bocchio-Chiavetto, V Bagnardi… - The World Journal of …, 2010 - Taylor & Francis
Objectives. Alterations of BDNF signalling in major depression (MD) are supported by
studies demonstrating decreased levels of the neurotrophin serum and plasma content in …

Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression

C Zhou, J Zhong, B Zou, L Fang, J Chen, X Deng… - PloS one, 2017 - journals.plos.org
Background Brain derived neurotrophic factor (BDNF) is one of the most important
regulatory proteins in the pathophysiology of major depressive disorder (MDD). Increasing …

Effects of antidepressant treatment on neurotrophic factors (BDNF and IGF-1) in patients with major depressive disorder (MDD)

A Mosiołek, J Mosiołek, S Jakima, A Pięta… - Journal of clinical …, 2021 - mdpi.com
Major depressive disorder (MDD) remains the subject of ongoing research as a multifactorial
disease and a serious public health problem. There is a growing body of literature focusing …

The microbiota–gut–brain axis and its modulation in the therapy of depression: Comparison of efficacy of conventional drugs and traditional Chinese medicine …

C Bi, S Guo, S Hu, J Chen, M Ye, Z Liu - Pharmacological Research, 2022 - Elsevier
Depression is a common and severe mental disease that places a heavy burden on human
society, which can lead to decreased cognitive function, energy loss, insomnia, and even …

Creatine, similar to ketamine, counteracts depressive-like behavior induced by corticosterone via PI3K/Akt/mTOR pathway

FL Pazini, MP Cunha, JM Rosa, ARS Colla… - Molecular …, 2016 - Springer
Ketamine has emerged as a novel strategy to treat refractory depression, producing rapid
remission, but elicits some side effects that limit its use. In an attempt to investigate a safer …

Resveratrol ameliorates depressive-like behavior in repeated corticosterone-induced depression in mice

SH Ali, RM Madhana, KV Athira, ER Kasala… - Steroids, 2015 - Elsevier
A mouse model of depression has been recently developed by exogenous corticosterone
(CORT) administration, which has shown to mimic HPA-axis induced depression-like state in …